VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

Bullboard Posts

Comment by Super1nvestoron Mar 23, 2017 7:34pm

111 Views

Post# 26023261

RE:Dr. Adams perspective re: 3D/4D echo

Thank you for that post Frank. That makes pretty good sense...so, basically the margin of error and lack of accuracy is still the main issues with the 3D/4D scans. Looks like VPT has leapfrogged the bigger more well-known companies with better tech at the 2D level that is faster, more accurate, less expensive and can be learned a lot faster as well by cardiologists. To me that = big win in my books!

SailorFrank wrote: My first post. After taking a position in VPT I saw the various posts about 3D/4D questioning how VMS could possibly compete. So I sent investor relations the question this morning and received the following response from Dr. Adams.....below.

Frank,

Thanks for the interest.

3D/4D US is getting better but it still only provides a readable scan 50% of the time, so it is not used for routine clinical cardiac (need 80%). In the readable scans, the volumes are underestimated by 15% (very poor accuracy) and the standard error is 30% (very poor precision). So 3/4D volume measurements still need a lot of work.

If you pick the best scans and spend an hour doing the analysis you can get decent accuracy and precision if you are an expert (done about 120 cases, so takes months to get good at it).

The VMS has accuracy +/- 2% and error +/- 7% and takes 7 minutes to do and you become an expert after 5 cases (an hour).

We will make 3/4D work as we have the way to make thew analysis fully automated. Next product!

We only hope that GE, Seimnes, phillips, Toshiba, Samsung, Fuji…make 3/4D work better so we can get to 80% readable scans.

Regards,

George Adams, PhD, ICD.D

President and CEO

Ventripoint Diagnostics Ltd..